Dataset Information

Global discovery of synapse proteins using multi-omic synaptic signatures

ABSTRACT: Bottom-up proteomics analysis of whole cell lysate and synaptosomes extracted from wild type and Cul3-haploinsufficient mouse cortex

INSTRUMENT(S):

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Brain

SUBMITTER: Justin McKetney

LAB HEAD: Nevan J Krogan

PROVIDER: PXD041108 | Pride | 2026-03-09

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	YKM2_Cyto_wLib_Library.tsv.speclib	Tabular
	YKM2_Syn_wLib_Results.tsv	Tabular
	YKM2_Syn_wLib_Results_Library.tsv.speclib	Tabular
	YKM2_wLib_CytoResults.tsv	Tabular
	checksum.txt	Txt

Items per page:

1 - 5 of 69

Publications

Integrated multi-omic characterizations of the synapse reveal RNA processing factors and ubiquitin ligases associated with neurodevelopmental disorders.

Mei Yuan Y Gosztyla Maya L ML Tan Xinzhu X Dozier Lara E LE Wilkinson Brent B McKetney Justin J Lee John J Chen Michael M Tsai Dorothy D Kopalle Hema H Gritsenko Marina A MA Hartel Nicolas N Graham Nicholas A NA Flores Ilse I Gilmore-Hall Stephen K SK Xu Shuhao S Marquez Charlotte A CA Liu Sophie N SN Fong Dylan D Chen Jing J Licon Kate K Hong Derek D Wright Sarah N SN Kreisberg Jason F JF Nott Alexi A Smith Richard D RD Qian Wei-Jun WJ Swaney Danielle L DL Iakoucheva Lilia M LM Krogan Nevan J NJ Patrick Gentry N GN Zhou Yang Y Feng Guoping G Coba Marcelo P MP Yeo Gene W GW Ideker Trey T

Cell systems 20250306 4

The molecular composition of the excitatory synapse is incompletely defined due to its dynamic nature across developmental stages and neuronal populations. To address this gap, we apply proteomic mass spectrometry to characterize the synapse in multiple biological models, including the fetal human brain and human induced pluripotent stem cell (hiPSC)-derived neurons. To prioritize the identified proteins, we develop an orthogonal multi-omic screen of genomic, transcriptomic, interactomic, and st ...[more]

PMID: 40054464

Similar Datasets

Project description:Objectives: Arterial hypertension (AH) influences salivary gland physiology and oral health, being associated with a higher incidence of periodontal disease in pregnant women. Evidence points to a bidirectional relationship between the oral microbiota and blood pressure regulation. Therefore, this study aimed to characterize the oral health of pregnant women and AH-associated changes in the salivary proteome and microbiome during pregnancy and postpartum. Design: Ten healthy women and ten women with AH were enrolled. Saliva was collected during pregnancy and six months postpartum. The salivary proteome was characterized by shotgun label-free mass spectrometry analysis. Specific proteins were validated through parallel reaction monitoring (PRM). The oral microbiota was characterized via 16S rRNA gene amplicon sequencing (V4 region). The periodontal health and the caries history was assessed during pregnancy. Results: Pregnant women with AH had lower junction plakoglobin (JUP)- and desmoplakin (DSP)-specific peptide levels than healthy women, confirmed by the PRM approach. The levels of these proteins correlated negatively with periodontal health indexes, which were higher in pregnant women with AH. In AH, nitrate-reducing microorganisms had lower abundance, correlating positively with JUP and DSP-specific peptides. Conclusions: The salivary proteome and microbiota are shaped by AH during and after pregnancy. Further research is required to understand the underlying mechanisms impairing oral health in AH. Data acquisition has been supported by EPIC-XS, project number 393, funded by the Horizon 2020 program of the European Union and the National Institute for Neurological Research (Programme EXCELES, ID Project No. LX22NPO5107) and the MEYS/EU project OP JAK-MULTIOMICS_CZ - Multi-omics platform for the search for biological correlates of diseases and the development of new diagnostic, preventive and therapeutic procedures (CZ.02.01.01/00/23_020/0008540).

Project description:Breast cancer (BC) remains the leading cause of cancer-related death among women worldwide, with 2.26 million new cases and ~685,000 deaths reported in 2020 (Globocan 2020). A major challenge in treating BC, particularly luminal subtypes, is the pronounced molecular heterogeneity both between patients and within individual tumours. This intratumoural diversity underlies many cases of therapy resistance and relapse. Here, we present a theranostic approach that integrates spatial proteomics and patient-derived tumoroids (PDTs) to guide personalized treatment in luminal BC. Formalin-fixed, paraffin-embedded (FFPE) tumour tissues from three patients were analyzed by MALDI mass spectrometry imaging (MSI) and spatially-resolved micro-proteomics, mapping distinct clonal subpopulations and their protein expression profiles. Proteomic pathway analysis revealed subclone-specific vulnerabilities that are not apparent from standard histopathology. We exploited these insights to design alternative combination therapies tailored to each tumour’s molecular makeup. The efficacy of proteomics-guided regimens was then evaluated in vitro using PDTs established from the same patients, in direct comparison to conventional chemotherapy. Proteomic-informed treatments demonstrated significantly enhanced anti-tumour activity in the PDT models, yielding lower IC₅₀ values and greater cell death than standard treatments. In several cases, PDTs exhibited resistance to conventional therapy, which was explained by the presence of proteomic resistance markers (such as EDIL3, CA12, PGK1, and CapG) in the corresponding tumour clones. These results underscore the potential of spatial proteomic profiling to expose actionable intratumoural heterogeneity and to inform more effective, clone-specific therapies. Our study highlights an innovative pipeline for luminal BC therapy guidance, combining MALDI MSI and PDT drug testing, and advocates for the integration of spatial proteomics into precision oncology to improve treatment outcomes.